Oxfendazole
Small molecule
Oxfendazole is one of 8 small molecule programs targeting Cysticercosis. It is currently in development.
1
Indications
9
Total Trials
4
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Cysticercosis
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Prilosec
DDexcel Pharma Technologies Ltd.
Phase 3
Biltricide
BayerPhase 2
Albendazole and Praziquantel
UUniversidad Peruana Cayetano Heredia
Phase 3
Albendazole.
GSKPreclinical
Dilantin
VViatris Specialty LLC
Preclinical
PBR28
NNational Institute of Mental Health (NIMH)
Phase 1
Oxfendazole
UUniversidad Peruana Cayetano Heredia
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment2 trials
Fascioliasis1 trial
Safety and Efficacy1 trial
Trial1 trial
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02234570·70 enrolled
3 more indications
Adult1 trial
Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03035760·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxfendazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]